B-type natriuretic peptide (BNP), a clinical biomarker for cardiovascular disease (CVD), is
secreted by cardiac tissue in response to neurohormonal stresses. However, BNP is …

Background B-type natriuretic peptide (BNP) is known to be a risk marker following acute
myocardial infarction (MI). More recently, truncated molecular forms of the BNP molecule …

Recent studies report that, in the absence of heart failure and renal failure, plasma B-type
natriuretic peptide (BNP) has prognostic value for mortality. We sought to confirm and extend …

Aim: Patients with elevated levels of B-type natriuretic peptide (BNP) and/or NT-proBNP as
measured by clinical tests have an elevated risk of heart failure (HF). Despite utility in large …

BACKGROUND B-type natriuretic peptide (BNP) molecular forms 5-32, 4-32, and 3-32 are
known to be present in the circulation of heart failure (HF) patients. This study investigated …

B-type natriuretic peptide (BNP) is produced by cardiomyocytes and promotes natriuresis
and vasodilatation and thereby counteracts the deleterious effects of the sympathetic …

Background Circulating B-type natriuretic peptide (BNP) is widely accepted as a diagnostic
and risk assessment biomarker of cardiac function. Studies suggest that there are significant …

Background—Measurement of B-type natriuretic peptide (BNP) concentration or its
precursor (N-terminal fragment [NT-proBNP]) is recommended in patients with symptoms of …

Cardiac secretion of B-type natriuretic peptide (BNP) increases with the progression of heart
failure (HF), and plasma measurement of BNP has emerged recently as a useful, cost …

Simple Summary Active BNP-32, less active proBNP-108, and inactive N-terminal proBNP-
76 all circulate in the blood. The circulating protease neprilysin has lower substrate …